18 May 2020 

The Canadian Center for Vaccinology (CCfV) at Dalhousie University has received approval from Health Canada to conduct the country’s first clinical trials of a potential Covid-19 vaccine, which has been developed by Chinese company CanSino Biologics. The trials are expected to be commenced in the coming two weeks following ethics board approval.

The UK Government will provide £84m in funding and manufacturing support for the University of Oxford and Imperial College London researchers working on Covid-19 vaccine programme. Also, Oxford University signed global licensing deal with AstraZeneca, which agreed to produce up to 30 million vaccine doses by September.

Sorrento Therapeutics has reported that its Covid-19 antibody candidate, STI-1499, was able to completely block the virus infection during in-vitro preclinical studies. The company intends to develop an antibody cocktail that would protect from Covid-19.

Cigarette company British American Tobacco (BAT) is ready to study in human clinical trials of its Covid-19 vaccine candidate made using proteins from tobacco leaves, according to Reuters. The vaccine candidate is said to have shown positive immune response in pre-clinical studies. On 15 May, the company filed a pre-investigative new drug application with the US Food and Drug Administration (FDA), which acknowledged the submission.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.